ELISA (Enzyme-Linked Immunosorbent Assay) is a widely used analytical biochemistry technique that employs enzyme-labeled antibodies to detect and quantify specific proteins, antigens, antibodies, and other biomolecules in biological samples. This plate-based immunoassay has become indispensable in preclinical research for biomarker discovery, drug development, toxicology screening, and therapeutic monitoring due to its high specificity, sensitivity, and throughput capabilities in contract research settings.
Technology Fundamentals and Mechanism
ELISA is a heterogeneous EIA technique used in clinical analyses where one of the reaction components is nonspecifically adsorbed or covalently bound to the surface of a solid phase, such as a microtiter well, magnetic particle, or plastic bead. The enzyme linked immunosorbent assay is a powerful method for detecting and quantifying a specific protein in a complex mixture, originally described by Engvall and Perlmann in 1971.
Two different research teams simultaneously invented the direct ELISA: scientists Engvall and Perlman and scientists Van Weemen and Schuurs. The ELISA was developed by modification of the radioimmunoassay (RIA) by conjugating tagged antigens and antibodies with enzymes rather than radioactive iodine 125. The technique enables separation of bound and free-labeled reactants through solid-phase immobilization.
ELISA Formats and Applications
ELISA techniques are broadly classified into direct, indirect, sandwich, and competitive ELISA, all of which vary based on the antigens, antibodies, substrates, and experimental conditions. Sandwich ELISA, the most commonly used format, requires two antibodies specific to different epitopes of the antigen.
In the most common approach, an aliquot of sample or calibrator containing the antigen to be quantified is added to and allowed to bind with a solid-phase antibody. After washing, an enzyme-labeled antibody is added and forms a “sandwich complex” of solid-phase Ab-Ag-Ab enzyme. The sandwich assay uses a pair of monoclonal antibodies against different epitopes against the same target, with the primary mAb bound to the plate pulling the protein out of solution.
Preclinical Research Applications
ELISAs represent one of the simplest assay formats to perform, offering rapid, quantitative, and sensitive analyte detection at relatively low cost. The ease of adapting an ELISA to a higher throughput screening method empowers researchers to test large sample numbers in a single run.
The rigorous validation of commercially available mouse and rat endostatin ELISA shows that it meets all requirements for robust, reliable and fast measurement, and can be used in pre-clinical research for further investigations. ELISAs are extensively used for studying soluble protein biomarkers in various matrices including serum, plasma, cell culture supernatant, and cell lysates.
Biomarker Discovery and Validation
As a result, the FDA and EMA have introduced formal biomarker qualification processes that offer regulatory stamp of approval, validating the biomarker’s suitability for use in drug development. A staggering 77 percent of biomarker challenges were linked to assay validity, with frequent issues including problems with specificity, sensitivity, detection thresholds and reproducibility.
Biomarkers are used in many scientific fields and are measured for diagnosis of disease, dividing the stage of disease, and can be used to evaluate the effect and safety of new pharmacy and therapy on humans. Advanced technologies like MSD and LC-MS/MS offer enhanced precision and sensitivity for biomarker analysis, with MSD providing up to 100 times greater sensitivity than traditional ELISA.
Drug Development and Immunogenicity Assessment
Humanized monoclonal antibody therapeutics are in many ways indistinguishable from anti-therapeutic/anti-drug antibodies generated in humans, making immunogenicity assessments pose unique challenges in clinical trials. ELISA is the most commonly used assay platform for detection and quantification of anti-drug antibodies in serum or plasma samples.
During clinical development and preclinical toxicology studies where drug is administered at multiple-fold above clinical doses, samples collected to evaluate anti-drug antibodies are expected to contain high levels of circulating drug. Sample pretreatment methods with acid for dissociation of drug:anti-drug complexes have been developed to overcome drug interference.
Technical Specifications and Performance
ELISAs are typically performed in 96-well or 384-well polystyrene plates, which passively bind antibodies and proteins. High sensitivity and specificity are common for ELISAs to detect antigens at the picogram level in a very specific manner due to the use of antibodies.
The sensitivity of traditional enzyme-linked immunosorbent assays is limited by the low binding avidity and heterogeneous orientation of capture antibodies coated on polystyrene-based microplates. Development of highly sensitive ELISA strategies using poly-protein G-expressing cells on microplates can improve coating amount and displayed orientation of capture antibodies.
Automation and High-Throughput Applications
In recent years, there has been a significant increase in outsourcing of biomarker testing to contract research organizations (CROs). While an ELISA is easy to set up, the assay procedure is time-consuming and labor-intensive. Laboratory automation for high-throughput plate-based assay workflows can help with providing walkaway time and increasing throughput.
MarinBio’s scientists have developed ELISAs to detect analytes in complex matrices like blood, plasma, serum, and cell culture media, created 90-minute GMP ELISA, and manufactured thousands of kits for distribution to hospital med-tech labs. Automated systems enable processing of large sample numbers with improved reproducibility and reduced hands-on time.
Advanced ELISA Technologies
eSimoa (enzyme-linked single molecule array) represents a significant evolution of traditional ELISA technique by enabling enzymatic reaction measurements at the single-molecule level, which dramatically improves detection limits. This method allows precise quantification of low-abundance proteins and activity of critical enzymes such as protein kinases and telomerases.
Cell-based ELISA methods have been developed as cost-effective and reliable alternatives to flow cytometry for assessment of binding activity of therapeutic antibodies. These approaches provide economical, robust and reliable methods for potency estimation of biological drugs.
Clinical and Diagnostic Applications
Researchers consider ELISA to be the gold standard of immunoassays. Tests that use ELISA can help diagnose a wide range of conditions, from bacterial and viral infections to endocrine conditions. Home pregnancy tests are based on the ELISA technique, detecting the presence of human chorionic gonadotrophin (HCG).
ELISA has been used as a diagnostic tool in medicine, plant pathology, and biotechnology, as well as a quality control check in various industries. Applications include detection of allergens, serological blood tests, toxicology screening, and SARS-CoV-2 antibody detection.
Validation and Quality Control
Validation according to ICH and EMEA guidelines demonstrates that assays can be used reliably and reproducibly for detection in animal samples and may give new perspectives within biomarker research. MarinBio has validated bispecific antibody ELISA to FDA GLP standards for PK analysis and can adapt the technology to detect other bispecific antibodies in GLP or cGMP assays.
The Conferma ELISA brand consists of sandwich assays designed to minimize lot-to-lot variability at the critical reagent level, with detailed quality control protocols to control and limit variability over time. Proper validation includes assessment of specificity, sensitivity, accuracy, precision, and robustness parameters.
Anilocus provides comprehensive ELISA services including custom assay development, biomarker detection, and immunogenicity assessment for preclinical research applications. Our facility offers validated sandwich, competitive, and direct ELISA formats with complete analytical support for drug development, safety testing, and therapeutic monitoring programs. Our specialized capabilities include high-throughput screening, GLP-compliant validation, and advanced detection technologies to support regulatory submissions and clinical translation of therapeutic candidates.
Contact us for specialized ELISA assay development and bioanalytical services.